Abstract:Objective To explore the effect of vasoactive intestinal peptide (VIP) on brain-derived neurotrophic factor (BDNF) in the visual cortex of form-deprived amblyopia rats, and to explore the mechanism of neuroprotective effect of amblyopia treatment.Method Thirty-six three-week-old healthy SD rats were selected and randomly divided into control, model and treatment groups, 12 in each group. The visual acuity of rats was measured using the forepaw touchdown test, the objective visual function was measured by pattern visual evoked potentials (PVEP), and the expression level of BDNF in the visual cortex of rats in each group was detected using Western blotting, immunofluorescence staining was used to observe the expression levels of glial fibrillary acidic protein (GFAP) and VIP in the visual cortex and the sites of GFAP expression, pathological changes in the rat visual cortex observed by HE staining.Result Compared with the model group, visual acuity and the objective visual function of the treatment group was significantly improved (P < 0.05), and the BDNF protein expression level was significantly increased (P < 0.05), but still lower than that of the control group (P < 0.05). Immunofluorescence assay results showed: GFAP-positive cells in the normal and amblyopic groups were mainly expressed in layers Ⅰ and Ⅵ of the visual cortex, and the fluorescence intensity of GFAP in the visual cortex of rats in the amblyopic group was significantly lower than that of the control group (P < 0.05), while the fluorescence intensities of VIP and GFAP in the visual cortex of the treated group were significantly increased (P < 0.05).Conclusion VIP has a therapeutic effect on amblyopic rat, which may be related to the release of BDNF from astrocytes in the activated visual cortex, and this study provides new thoughts on the treatment of amblyopia.